Chronic Constipation Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2032

The Chronic Constipation market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Abbott, AstraZeneca Plc, Cosmo Pharmaceuticals NV, Sanofi, Bayer AG, Valeant Pharma, Pfizer Inc., Takeda Pharma, Ironwood Pharmaceuticals, Salix Pharmaceuticals, Synergy Pharma, Janssen Pharmaceutical, Boehringer Ingelheim

[Nevada, United States] - DelveInsight's "Chronic Constipation Market Insights, Epidemiology, and Market Forecast 2032." report offers a detailed examination of Chronic Constipation, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Chronic Constipation Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/chronic-constipation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Chronic Constipation Market Report:
• The Chronic Constipation market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2019-2032).
• In July, 2024: AbbVie announced a Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation
• In June, 2024: Vibrant Ltd. announced that their study was performed to assess the safety and efficacy of the vibrant capsule vs. placebo for the treatment of subjects with functional Constipation.
• Enck et al.(2015), reported variable prevalence rates between 2.4 and 35%for chronic constipation acrossdifferent countries worldwide, with a low 5% for Germany
• As per Roque et al. (2015), a population-based study reported that the cumulative incidence of chronicconstipation (CC) is higher in the elderly (~20%) compared to a younger population. Severe constipation ismore common in elderly women, with rates of constipation two to three times higher than that of theirmale counterparts.
• According to Yamamoto et al. (2022), in an online survey conducted in the USA, the prevalence of chronicconstipation was reported to be 5.5% according to the Rome III criteria, and it was found to be2.1%basedon medical consultations in Japan
• Key Chronic Constipation Companies are as follows: Abbott, AstraZeneca Plc, Cosmo Pharmaceuticals NV, Sanofi, Bayer AG, Valeant Pharma, Pfizer Inc., Takeda Pharma, Ironwood Pharmaceuticals, Salix Pharmaceuticals, Synergy Pharma, Janssen Pharmaceutical, Boehringer Ingelheim
• Key Chronic Constipation Therapies are as follow: LINZESS (linaclotide), GOOFICE, ANJ908 (Pradigastat), YH12852, A3309, AJG555, linaclotide, ASP0456, KWA-0711, Tegaserod, prucalopride, TD-5108, linaclotide acetate, Prucalopride, PEG 4000, Lubiprostone, prucalopride
• Launching multiple stage Chronic Constipation pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Chronic Constipation market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/report-store/chronic-constipation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Chronic Constipation Overview:
Constipation is very common and many or most people are affected at some time in their life. However, for upto a quarter of the population it is more than a minor annoyance, it can be chronic, sometimes severe, and has a significant, even debilitating, effect on their quality of life. Chronic constipation can be uncomfortable and can interfere with a persons day-to-day functioning. While some causes of the condition are relatively benign and highly treatable, others can be more serious.

Chronic Constipation Epidemiology Segmentation:
The Chronic Constipation market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Chronic Constipation Total Prevalence
• Chronic Constipation Diagnosed Prevalence
• Chronic Constipation Gender-specific Diagnosed
• Chronic Constipation Age-specific Diagnosed Prevalence

For more information about Chronic Constipation companies working in the treatment market, visit https://www.delveinsight.com/sample-request/chronic-constipation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Chronic Constipation Market Insights
The global chronic constipation market is witnessing a robust growth trajectory due to the increasing prevalence of gastrointestinal disorders, a rising elderly population, and growing awareness about gastrointestinal health. As of 2024, the market is valued at over USD 8.5 billion, with projections indicating a compound annual growth rate (CAGR) of around 5-6% over the next five years.

Chronic Constipation Drugs Uptake
• Linzess remains one of the most widely prescribed medications for chronic idiopathic constipation and IBS-C. Its uptake has been consistent, particularly in the U.S. and European markets, due to its ability to increase intestinal fluid secretion and improve bowel movements.
• Amitiza, a chloride channel activator, is a mainstay in the treatment of chronic constipation, especially among patients with CIC and OIC. The drug's uptake remains strong due to its efficacy in easing stool passage and its favorable safety profile.
• Approved by the FDA in 2018, Motegrity has gained traction in both the U.S. and European markets. It works as a serotonin-4 receptor agonist, promoting bowel motility, making it an ideal option for patients who do not respond to traditional therapies.
• Movantik, a PAMORA, is specifically targeted at treating opioid-induced constipation. Its uptake is significant among patients on long-term opioid therapy, helping to counteract the gastrointestinal side effects of opioid medications.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/chronic-constipation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Chronic Constipation Therapies and Key Companies:
• LINZESS (linaclotide): ABBVIE
• GOOFICE: Eisai Co., Ltd.
• ANJ908 (Pradigastat): Anji Pharma
• YH12852: Yuhan
• A3309: Albireo
• AJG555: EA Pharma Co., Ltd.
• linaclotide, ASP0456: Astellas Pharma Inc
• KWA-0711: Kissei Pharmaceutical Co., Ltd.
• Tegaserod: Novartis
• prucalopride: Movetis
• TD-5108: Theravance Biopharma
• linaclotide acetate: Ironwood Pharmaceuticals, Inc.
• Prucalopride: Movetis
• PEG 4000: Ipsen
• Lubiprostone: Takeda
• prucalopride: Shire

Chronic Constipation Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2019 to 2032. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Chronic Constipation.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/chronic-constipation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Chronic Constipation Market Drivers:
• Rising Prevalence of Gastrointestinal Disorders
• Shift from OTC to Prescription Medications
• Technological Advancements

Chronic Constipation Market Barriers:
• Availability of OTC Alternatives
• High Cost of Prescription Drugs
• Adverse Effects and Limited Long-term Data

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/chronic-constipation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Chronic Constipation Market Report:
• Study Period: 2019-2032
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Chronic Constipation Companies: Abbott, AstraZeneca Plc, Cosmo Pharmaceuticals NV, Sanofi, Bayer AG, Valeant Pharma, Pfizer Inc., Takeda Pharma, Ironwood Pharmaceuticals, Salix Pharmaceuticals, Synergy Pharma, Janssen Pharmaceutical, Boehringer Ingelheim
• Key Chronic Constipation Therapies: LINZESS (linaclotide), GOOFICE, ANJ908 (Pradigastat), YH12852, A3309, AJG555, linaclotide, ASP0456, KWA-0711, Tegaserod, prucalopride, TD-5108, linaclotide acetate, Prucalopride, PEG 4000, Lubiprostone, prucalopride
• Chronic Constipation Therapeutic Assessment: Current marketed and emerging therapies
• Chronic Constipation Market Dynamics: Chronic Constipation Market drivers and Chronic Constipation barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chronic Constipation Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Chronic Constipation market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/chronic-constipation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1 Key Insights
2 Report Introduction
3 Chronic Constipation Market Overview at a Glance
4 Chronic constipation Executive Summary
5 Chronic constipation Key Events
6 Disease Background and Overview: Chronic constipation
7 Chronic Constipation Epidemiology and Patient Population
8 Chronic Constipation Patient Journey
9 Chronic Constipation Marketed Therapies
10 Chronic Constipation Emerging Therapies
11 Chronic Constipation: Seven Major Market Analysis
12 Key Opinion Leaders' Views
13 Chronic Constipation Unmet Needs
14 Chronic Constipation Market Drivers
15 Chronic Constipation Market Barriers
16 SWOT Analysis
17 Chronic Constipation Market Access and Reimbursement
18 Appendix
19 DelveInsight Capabilities
20 Disclaimer
21 About DelveInsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.